🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 107 of 173

  1. US 8637239

    Minimally-invasive measurement of esophageal inflammation

    Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8637013

    Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis

    Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8637011

    Modulation of NKG2D

    Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8632510

    Nanochanneled device and related methods

    Expires Mon Jan 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8633154

    Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth

    Expires Mon Jan 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8633034

    Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution

    Expires Mon Jan 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8628917

    Genes of an otitis media isolate of nontypeable Haemophilus influenzae

    Expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8629127

    Compositions and methods of treatment for inflammatory diseases

    Expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8629119

    Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders

    Expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8628769

    Modified vitamin K-dependent polypeptides

    Expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8629141

    Spiro-oxindole MDM2 antagonists

    Expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8623397

    Delivery device and method for forming the same

    Expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8624032

    Compound libraries made through phosphine-catalyzed annulation/Tebbe/Diels-Alder reactions

    Expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8623841

    Medical and nutritional applications of highly refined cellulose

    Expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8623832

    Peptide compositions that bind TLR-4

    Expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8623847

    Compositions for treatment of inflammatory diseases

    Expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8623917

    Uses of prostacyclin analogs

    Expires Mon Jan 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8617815

    Molecules with effects on cellular development and function

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8617549

    Bispecific nanobodies as a therapeutic for alzheimer's disease

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8618324

    Composition and method for making oligo-benzamide compounds

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8618167

    Methods of attenuating cognitive deficits with sulfonyl fluorides

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8618096

    Prodrug compositions and methods for using the same in treating cancer and malaria

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8618074

    GPCR enhanced neuroprotection to treat brain injury

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8617557

    Antibody fusion with IL-12 proteins with disrupted heparin-binding activity

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8617538

    Mesodermal-like cell population for treating ischemia in mammals

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8617143

    Therapeutic agent delivery systems and devices

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8617132

    Bioresorbable embolization microspheres

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8613944

    Compositions and methods for separating tissue

    Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8613904

    Methods for diagnosis and intervention of hepatic disorders

    Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8614082

    Attenuation of encephalitogenic alphavirus and uses thereof

    Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8613900

    Nanostructured transition metal oxides useful for water oxidation catalysis

    Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8609417

    Methods and compositions for stem cell cultures

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8609412

    Mapc generation of lung tissue

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8609404

    Vaccines containing canine parvovirus genetic variants

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8609334

    Biomarkers for painful intervertebral discs and methods of use thereof

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8609067

    Method of measuring propulsion in lymphatic structures

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8609088

    Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8609843

    Photoactive metal nitrosyls for blood pressure regulation and cancer therapy

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8609682

    Analgesic agents

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8609608

    Antimicrobial peptides

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8609661

    Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor

    Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8603819

    Compositions and methods for generating musculoskeletal tissue

    Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8604074

    Pro-neurogenic compounds

    Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8604023

    1,4-benzodiazepinone compounds and their use in treating cancer

    Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8604011

    Therapy for treatment of chronic degenerative brain diseases and nervous system injury

    Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8603543

    Mesocellular oxide foams as hemostatic compositions and methods of use

    Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8598313

    Compositions for ameliorating cell proliferative disorders and methods of making and using them

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8598321

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.